Free Trial
NASDAQ:GNFT

Genfit (GNFT) Stock Price, News & Analysis

Genfit logo
$3.67 -0.15 (-3.93%)
(As of 12/24/2024 05:19 PM ET)

About Genfit Stock (NASDAQ:GNFT)

Key Stats

Today's Range
$3.63
$3.94
50-Day Range
$3.66
$6.37
52-Week Range
$3.31
$6.42
Volume
5,231 shs
Average Volume
15,665 shs
Market Capitalization
$183.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00
Consensus Rating
Buy

Company Overview

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Genfit Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
25th Percentile Overall Score

GNFT MarketRank™: 

Genfit scored higher than 25% of companies evaluated by MarketBeat, and ranked 837th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Genfit has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Genfit has only been the subject of 1 research reports in the past 90 days.

  • Read more about Genfit's stock forecast and price target.
  • Earnings Growth

    Earnings for Genfit are expected to decrease in the coming year, from $0.98 to ($0.58) per share.

  • Price to Book Value per Share Ratio

    Genfit has a P/B Ratio of 2.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.13% of the float of Genfit has been sold short.
  • Short Interest Ratio / Days to Cover

    Genfit has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in Genfit has recently increased by 1.43%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Genfit does not currently pay a dividend.

  • Dividend Growth

    Genfit does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.13% of the float of Genfit has been sold short.
  • Short Interest Ratio / Days to Cover

    Genfit has a short interest ratio ("days to cover") of 4.4.
  • Change versus previous month

    Short interest in Genfit has recently increased by 1.43%, indicating that investor sentiment is decreasing.
    • Insider Buying vs. Insider Selling

      In the past three months, Genfit insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 4.20% of the stock of Genfit is held by insiders.

    • Percentage Held by Institutions

      Only 2.24% of the stock of Genfit is held by institutions.

    • Read more about Genfit's insider trading history.
    Receive GNFT Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter.

    GNFT Stock News Headlines

    Has Trump Finally Gone Too Far?
    Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.
    Genfit’s Revenue Surge Driven by Key Milestone
    GENFIT Reports Third Quarter 2024 Financial Information
    See More Headlines

    GNFT Stock Analysis - Frequently Asked Questions

    Genfit's stock was trading at $3.85 at the start of the year. Since then, GNFT stock has decreased by 4.7% and is now trading at $3.67.
    View the best growth stocks for 2024 here
    .

    Genfit (GNFT) raised $132 million in an IPO on Wednesday, March 27th 2019. The company issued 5,000,000 shares at a price of $26.33 per share. SVB Leerink and Barclays served as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers.

    Shares of GNFT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
    Compare Top Brokerages Here.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Genfit investors own include Intercept Pharmaceuticals (ICPT), InterDigital (IDCC), NVIDIA (NVDA), Occidental Petroleum (OXY), Vaxart (VXRT), American Airlines Group (AAL) and Carnival Co. & (CCL).

    Company Calendar

    Today
    12/24/2024
    Fiscal Year End
    12/31/2024

    Industry, Sector and Symbol

    Sector
    Medical
    Industry
    Biological products, except diagnostic
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:GNFT
    Fax
    N/A
    Employees
    120
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $13.00
    High Stock Price Target
    $13.00
    Low Stock Price Target
    $13.00
    Potential Upside/Downside
    +254.2%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    1 Analysts

    Profitability

    Pretax Margin
    N/A

    Debt

    Sales & Book Value

    Annual Sales
    $76.06 million
    Book Value
    $1.48 per share

    Miscellaneous

    Free Float
    47,893,000
    Market Cap
    $183.47 million
    Optionable
    Not Optionable
    Beta
    1.15
    A Guide To High-Short-Interest Stocks Cover

    MarketBeat's analysts have just released their top five short plays for January 2025. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

    Get This Free Report

    This page (NASDAQ:GNFT) was last updated on 12/25/2024 by MarketBeat.com Staff
    From Our Partners